Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.16

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $1.16, but opened at $1.20. Adaptimmune Therapeutics shares last traded at $1.17, with a volume of 186,363 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research note on Friday, December 29th. They issued a “hold” rating on the stock.

Adaptimmune Therapeutics Stock Performance

The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1.87 and a beta of 2.39. The firm’s 50-day simple moving average is $1.41 and its 200-day simple moving average is $0.92.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $4.80 million. Adaptimmune Therapeutics had a negative return on equity of 155.39% and a negative net margin of 188.90%. Equities research analysts forecast that Adaptimmune Therapeutics plc will post -0.44 earnings per share for the current year.

Institutional Trading of Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Columbia Advisory Partners LLC acquired a new stake in Adaptimmune Therapeutics in the 1st quarter worth $25,000. Two Sigma Investments LP bought a new position in shares of Adaptimmune Therapeutics during the 4th quarter worth about $33,000. UBS Group AG lifted its holdings in shares of Adaptimmune Therapeutics by 1,090.8% during the 4th quarter. UBS Group AG now owns 23,625 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 21,641 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Adaptimmune Therapeutics by 56.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 48,077 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 17,332 shares during the period. Finally, Twin Focus Capital Partners LLC bought a new position in shares of Adaptimmune Therapeutics during the 4th quarter worth about $44,000. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.